ABSTRACT
Objective To study the effect of Bairui granule and Deacetylated Ligustrazin injection on plasma BNP and FABP levels in children with heart failure and pneumonia.Methods 60 children of heart failure and pneumonia who received therapy from July 2014 to June 2016 in our hospital were randomly divided into two groups, the observation group and the control group, 30 cases in each group.children in the observation group were treated with sodium phosphate creatine, and the control group was treated with 2-linolenic acid,the clinical outcomes, clinical signs, BNF, FABP, LVEF and LVEDP were compared between the two groups.Results After treatment, the total effective rate of the observation group was significantly higher than that of the control group, the difference was statistically significant (P<0.05); The heart rate, respiratory rate and blood oxygen saturation of the two groups were significantly improved compared with those before treatment ( P<0.05 ) , the heart rate and respiratory rate of the observation group were lower than those of the control group, the oxygen saturation was higher than that of the control group (P<0.05).After treatment, the BNF and FABP indexes of the two groups were lower (P<0.05), and the BNF and FABP indexes in the observation group were lower than those in the control group (P<0.05); The LVEF of the observation group was higher than that of the control group, the LVEDP index was lower than that of the control group, the difference was statistically significant (P<0.05).Conclusion Bairui granule and Deacetylated Ligustrazin injection in the treatment of heart failure with pneumonia has a good effect in the process, which will help reduce the BNP index in children, recovery of children's body function.
ABSTRACT
Objective To investigate the relationship between wheezing and serum levels of 25-hydroxyvitamin D3.Methods 130 children with lower respiratory tract infection were selected as the subjects, the children with wheezing in group A([Abstract] Objective To investigate the relationship between wheezing and serum levels of 25-hydroxyvitamin D3.Methods 130 children with lower respiratory tract infection were selected as the subjects, the children with wheezing in group A(n=70),normal pneumonia (no wheezing) were group B(n=60); The healthy children who were examined in the hospital at the same period were selected as the control group (n=60). The serum levels of 25-hydroxyvitamin D3 were measured by ELISA in the control and hospitalized children. The pathogens and allergens of the two groups were also detected. Results The levels of serum 25-hydroxyvitamin D3 in group A and group B were (56.92±16.88) nmol/L, (70.68±21.96) nmol/L, respectively, which was significantly lower than that in control group (82.69±17.63) nmol/L, ( t=8.50, 3.30,P=0.00,0.00); compared with group A( t=3.85, P=0.00). The positive rate of group A was 65.71%, which was significantly higher than that of group B (35.00%, χ2=12.20,P=0.00). The positive rate of group A was 30.00% compared with the control group (35.00%, χ2=0.36,P=0.54). The serum level of 25-hydroxyvitamin D3 was 75.57% in group A, which was significantly higher than that in group B (60.00%,χ2=14.21, P=0.00). The positive rate of virus detection was 57.14% in 98 children with serum 25-hydroxy vitamin D3 level<75 nmol/L, which was significantly higher than that in serum 25-hydroxy vitamin D3 level≥75 nmol/L(18.75%, χ2=14.25, P=0.00). The positive rate of allergens in serum 25-hydroxy vitamin D3 level <75 nmol/L was 35.71%, which was significantly higher than that in serum 25-hydroxy vitamin D3 level≥75 nmol/L(21.88%, χ2=2.11, P=0.14). Conclusion The main risk factor for children with wheezing is viral infection, while the low level of serum 25-hydroxy vitamin D3 in children increases the risk of viral infection, resulting in increased risk of wheezing in patients,so the clinical can occur through the detection of serum 25- hydroxyvitamin D3 levels to predict and intervention for children with wheezing.
ABSTRACT
Objective To introduce inhaled inactivated-mycobacterium phlei on prevention and treatment of moderate bronchial asthma to observe the clinical effect. Method This study was a prospective and controlled study. The patients diagnosed with asthma in our out-patient from March 2009 to December 2010 were collected, who met the following conditions were included in the study: age≥ 14 years; met the criteria of moderate chronic persistent bronchial asthma in Global Initiative for Asthma (GINA) in 2008; suspended receiving systemic corticosteroids, Montelukast, ketotifen and other anti-inflammatory and anti-allergic drugs in one month; no significant respiratory tract infections; and other serious illnesses or abnormalities known.A total of 100 patients with asthma were selected, including 37 males and 63 females, age (32.11 ± 12.95 )years. The patients were randomly(random number) divided into two groups: A group(treatment group; 16males and 34 females, age 33.56 ± 14.23 years) and B group (control group; 21 males and 29 females,age 30.66 ± 11.50 years); 50 in each group. No significant difference was noted between the two groups on age and gender composition. The patients in A group were treated with inhaled inactivated-mycobacterium phlei F. U. 36 Injection 1.72 μg/mL × 2 that adding 3 mL normal saline, once a day for 5 days. The patients in B group were treated with salmeterol xinafoate and fluticasone propionate powder for inhalation (50/100 μg), twice daily for sustainable use. The patients in the two groups were observed for one month. During this course, the patients in the two groups could inhale the salbutamol sulphate aerosol as need to relieve symptoms. And the number of using was recorded. Pulmonary function test and asthma provocative test were carried out on the Day O, 6 and 31. ACT scores were measured before and after the treatment. Results On Day 6 and 31 after treatment, the negative conversion rates of asthma provocative test of the patients in A group were 82% and 78% respectively, B group were 84% and 90% respectively. Provocative test of the patients in the two groups were negative conversion significantly before and after treatment. There was no significant difference between the two groups by chi-square test (P ＞ 0. 05 ). Completely random designed data was analyzed by analysis of variance. The analysis showed that the accumulated doses of methacholine of the patients in the two group increased significantly ( P ＜ 0. 05 ), but no difference between the two groups.There was a improvement trend on forced expiratory volume in one second( FEV1 )of the patients in A group after treatment, but no difference. FEV1 of the patients in B group increased significantly higher ( P ＜0.05), which was significantly higher than A group on the 31th day (P ＜0. 05); Peak expiratory flow (PEF) of the patients in the two group increased significantly on Day 6 and 31 after treatment (P ＜0.05 ).On Day 31, B group was significantly higher than A group ( P ＜ 0. 05 ); Scores of asthma control test (ACT)of the patients in the two group were significantly increased, and the number of using of salbutamol sulfate aerosol was significantly reduced (P ＜0.01 ). B group was obvious than group A (P ＜0.05 ). During treatment, there were only two adverse reaction cases of transient low fever; most obvious was on the third day.Conclusions Inhaled inactivated-mycobacterium phlei would inhibit the airway hyperresponsiveness of the patients with moderate bronchial asthma in short time, improve the symptoms, reduce the acute exacerbation, and reduce the use of rescue medication, which has the roles of prevention and treatment of moderate asthma in a certain period of time.